Galapagos Reports Promising CAR T-Cell Therapy Results

Galapagos (GLPG) has released an update.

Galapagos has announced promising results from its Phase 1/2 study of the CD19 CAR T-cell therapy, GLPG5101, for relapsed/refractory non-Hodgkin lymphoma. The study, which was presented at the American Society of Hematology meeting, highlighted the therapy’s high antitumor activity and favorable safety profile, with a median vein-to-vein time of just seven days, allowing for quicker treatment without the need for cryopreservation.

For further insights into GLPG stock, check out TipRanks’ Stock Analysis page.